DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer

Information source: Aarhus University Hospital
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Lung Cancer

Intervention: Dalteparin (Fragmin®) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Thomas Decker Christensen

Official(s) and/or principal investigator(s):
Thomas D Christensen, MD, Principal Investigator, Affiliation: Aarhus University Hospital


The purpose of the study is: To estimate patients with lung cancers who will undergo surgery total haemostatic / thrombotic capacity pre, per-and postoperatively. To investigate whether prophylactic treatment with Low Molecular Weight Heparin (LMWH) affects the patient's potential hypercoagulability. To investigate whether there are differences in patients who will undergo Video Assisted Thorascopic Surgery (VATS) or open surgery in regards of impact of the coagulation system.

Clinical Details

Official title: Coagulation Profile in Patients Undergoing Video Assisted Thorascopic Surgery (VATS) for Lung Cancer - A Randomized, Controlled Trial

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Primary outcome: Thromboelastometry (ROTEM®)

Secondary outcome: Thrombin generation

Detailed description: Lung cancer is a serious and very frequent disease. For those 25% of the patients who will undergo surgery, there are two different methods of operation: either open surgery (thoracotomy) or Video Assisted Thorascopic Surgery (VATS). The latter method is increasing in use. Patients are often prescribed heparin pre- postoperatively, but it is unclear whether this prophylactic treatment is necessary, and it has never been thoroughly investigated. When patients receive heparin there is an increased risk of bleeding. Furthermore, it is unclear what changes occurs in the coagulation system pre, per- and postoperatively in patients undergoing surgery for lung-cancer, and hereby it is unclear whether these patients should have some sort of medical prophylactic treatment. By using new analysis methods in terms of Thromboelastometry, Thrombin generation and thrombocyte function analysis, hereby the total coagulation profile can be characterized and hereby estimate the risk of thrombosis and bleeding. Thereby better be able to give the right treatment for these patients.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Undergo surgery for lung cancer with an expected lobectomy or bilobectomy

- The surgery shall be VATS (for patients in the group randomized to other low

molecular weight heparin and no prophylactic)

- Willing to be randomized (VATS-patients)

- Over 18 years old.

- Able to give assigned informed consent

- Women should be prescribed secure anticonception.

Exclusion Criteria:

- Thromboembolic events within the last three months (both venous and arterial)

- Pregnant

- Lactating

- Treatment with anticoagulation therapy in terms of vitamin K antagonist or direct or

indirect thrombin inhibitors (dabigatran, apixaban or rivaroxaban)

- Treatment with thrombocyte function inhibitors in terms of Clopidogrel, ASA

(acetylsalicylic acid), prasugrel and ticagrelor, and no pause of minimum 5 days (7 days with regards of prasugrel) before surgery

- Allergy for LMWH

Locations and Contacts

Aarhus University Hospital, Aarhus 8200, Denmark

Rigshospitalet, Copenhagen, Denmark

Odense University Hospital, Odense, Denmark

Additional Information

Starting date: March 2013
Last updated: June 22, 2015

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017